Comparative Pharmacology
Head-to-head clinical analysis: FENTANYL versus QOLIANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENTANYL versus QOLIANA.
FENTANYL vs QOLIANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a synthetic opioid that primarily acts as a μ-opioid receptor agonist. It binds to μ-opioid receptors in the central nervous system (CNS), leading to G-protein-coupled receptor activation, inhibition of adenylate cyclase, decreased cAMP production, and modulation of ion channels (e.g., increased potassium efflux, decreased calcium influx). This results in hyperpolarization of neurons and reduced neurotransmitter release, producing analgesia, sedation, and euphoria. Fentanyl also has high lipid solubility, allowing rapid CNS penetration and a fast onset of action.
QOLIANA (elagolix) is a nonpeptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist that competitively binds to GnRH receptors in the pituitary gland, thereby reducing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to decreased ovarian production of estrogen and progesterone, resulting in a hypoestrogenic state.
25-100 mcg IV every 1-2 hours as needed; 50-100 mcg IM every 1-2 hours; transdermal patch: 12.5-100 mcg/h every 72 hours; transmucosal: 200-1600 mcg as single dose.
Initiate at 5 mg orally once daily, increase as tolerated to 10 mg once daily. Maximum dose 20 mg once daily.
Clinical Note
moderateFentanyl + Torasemide
"The risk or severity of adverse effects can be increased when Fentanyl is combined with Torasemide."
Clinical Note
moderateFentanyl + Etacrynic acid
"The risk or severity of adverse effects can be increased when Fentanyl is combined with Etacrynic acid."
Clinical Note
moderateFentanyl + Furosemide
"The risk or severity of adverse effects can be increased when Fentanyl is combined with Furosemide."
Clinical Note
moderateFentanyl + Bumetanide
None Documented
None Documented
Terminal elimination half-life is 3–12 hours (mean ~7 hours) in adults; prolonged in elderly, hepatic impairment, or with continuous infusion due to context-sensitive half-life.
Terminal elimination half-life is 12 hours (range 10–15 hours) in healthy adults; may extend to 18–24 hours in patients with moderate hepatic impairment (Child-Pugh B).
Primarily hepatic metabolism to norfentanyl and other inactive metabolites; renal excretion of metabolites accounts for ~75% of the dose (10% unchanged), with ~9% excreted in feces.
Renal excretion of unchanged drug accounts for approximately 30% of elimination; biliary/fecal excretion accounts for 60% (including metabolites); 10% is metabolized with negligible pulmonary elimination.
Category D/X
Category C
Opioid Agonist
Opioid Agonist
"The risk or severity of adverse effects can be increased when Fentanyl is combined with Bumetanide."